J.B. Chemicals & Pharmaceuticals growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+5.9%+9.6%
EBITDA+7.3%+16.8%
Net Income+7.6%+20.1%
EPS (adj.)+7.6%+20.1%
Total Assets+16.3%+11.8%
Total Equity+21.2%+18.8%
Free Cash Flow−10.0%—
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

JBCHEPHARM

J.B. Chemicals & Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersTORNTPHARMALKEMIPCALABSAILIFENHNEULANDLABACUTAASNATCOPHARM
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+5.9+9.6
EBITDA+7.3+16.8
Net Income+7.6+20.1
EPS (adj.)+7.6+20.1
Total Assets+16.3+11.8
Total Equity+21.2+18.8
Free Cash Flow-10.0—
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.